These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31687050)

  • 1. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
    Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Maksym J; Balsam P; Opolski G; Filipiak KJ
    Pol Arch Intern Med; 2019 Nov; 129(11):770-780. PubMed ID: 31642446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction.
    Huang WP; Zheng X; He L; Su X; Liu CW; Wu MX
    Chin Med J (Engl); 2018 Jun; 131(11):1282-1288. PubMed ID: 29786039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
    O'Donoghue ML; Morrow DA; Cannon CP; Jarolim P; Desai NR; Sherwood MW; Murphy SA; Gerszten RE; Sabatine MS
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
    Rabkin SW; Tang JKK
    Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention.
    Di Tano G; Caretta G; De Maria R; Parolini M; Bassi L; Testa S; Pirelli S
    Heart; 2017 Jan; 103(1):71-77. PubMed ID: 27465055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
    Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI.
    Liu X; Hu Y; Huang W; Zhang G; Cao S; Yan X; Li L; Zhang L; Zheng X
    Int Heart J; 2019 Jan; 60(1):19-26. PubMed ID: 30464124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR
    J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study.
    Miñana G; Núñez J; Bayés-Genís A; Revuelta-López E; Ríos-Navarro C; Núñez E; Chorro FJ; López-Lereu MP; Monmeneu JV; Lupón J; Bodí V
    Int J Cardiol; 2018 Nov; 270():336-342. PubMed ID: 29954670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
    Wojciechowska C; Romuk E; Nowalany-Kozielska E; Jacheć W
    Hellenic J Cardiol; 2017; 58(5):350-359. PubMed ID: 28363768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
    Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
    PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure.
    Barutaut M; Fournier P; Peacock WF; Evaristi MF; Dambrin C; Caubère C; Koukoui F; Galinier M; Smih F; Rouet P
    Acta Cardiol; 2020 Dec; 75(8):739-747. PubMed ID: 31560863
    [No Abstract]   [Full Text] [Related]  

  • 18. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
    Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
    BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
    Zhang Q; Hu M; Ma S
    J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.